ERBB2 and breast carcinoma: Results from the pivotal Cancer Genome Atlas (TCGA) project demonstrates that primary luminal breast cancers exhibit a lower mutation rate than other intrinsic subtypes, including basal-like and HER2-enriched breast cancers.